SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.99
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$20.10

27 Aug
2026

0.040

OPEN

$20.00

0.20%

HIGH

$20.28

2,411,897

LOW

$19.67

TARGET
$22.586 12.4% upside
Franking for last dividend paid out: 60%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MPL . MVF . NHF . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 123.1 123.5 xxx
DPS (cps) xxx 108.0 107.6 xxx
EPS Growth xxx 15.1% 0.3% xxx
DPS Growth xxx 0.9% - 0.4% xxx
PE Ratio xxx N/A 16.2 xxx
Dividend Yield xxx N/A 5.4% xxx
Div Pay Ratio(%) xxx 87.7% 87.1% xxx

Dividend yield today if purchased 3 years ago: 3.36%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.39

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/03 - ex-div 45c (franking 60%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx123.1
DPS All xxxxxxxxxxxxxxx108.0
Sales/Revenue xxxxxxxxxxxxxxx10,949.8 M
Book Value Per Share xxxxxxxxxxxxxxx1,687.5
Net Operating Cash Flow xxxxxxxxxxxxxxx1,405.5 M
Net Profit Margin xxxxxxxxxxxxxxx5.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx7.30 %
Return on Invested Capital xxxxxxxxxxxxxxx4.60 %
Return on Assets xxxxxxxxxxxxxxx3.64 %
Return on Equity xxxxxxxxxxxxxxx7.30 %
Return on Total Capital xxxxxxxxxxxxxxx7.77 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx240.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx742 M
Long Term Debt xxxxxxxxxxxxxxx5,097 M
Total Debt xxxxxxxxxxxxxxx5,840 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx654 M
Price To Book Value xxxxxxxxxxxxxxx1.23

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx735.6 M
Capex % of Sales xxxxxxxxxxxxxxx6.72 %
Cost of Goods Sold xxxxxxxxxxxxxxx7,922 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,942 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx227 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

21/08/2026

3

Hold

$20.80

3.48%

The title above the report says it all: Growth evaporates.

Ord Minnett maintains Sonic Healthcare on Hold with a revised target of $20.80 after FY27 guidance indicated little earnings growth despite FY26 revenue and EBITDA increasing 13% and 11%, respectively.

German synergies and US cost reductions are expected to be offset by reimbursement pressure, transformation expenses and higher depreciation and interest.

FY27-FY29 EPS forecasts fall -5.8%, -3.3% and -2.1%, respectively.

FORECAST
Ord Minnett forecasts a full year FY27 dividend of 110.00 cents and EPS of 123.00 cents.
Ord Minnett forecasts a full year FY28 dividend of 113.00 cents and EPS of 138.00 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

24/08/2026

3

Neutral

$22.90

13.93%

Jarden maintains its Neutral recommendation for Sonic Healthcare with its target price increased to $22.90 from $22.30 following an FY26 EBITDA result of $1,916m that met the midpoint of constant currency guidance and exceeded consensus expectations by 1%.

Underlying net profit after tax benefited from a lower effective tax rate of 25.9% compared to the guided 27%, though the outlook for FY27 disappointed due to headwinds including a Swiss funding cut, a wage equalisation payment in the UK, and delays in the NHS contract.

The broker's estimates reflect near-term earnings per share reductions of -3%-5%, while the analyst notes that FY28 is positioned to deliver operating leverage supported by forecasted revenue growth of 5%.

FORECAST
Jarden forecasts a full year FY27 dividend of 109.00 cents and EPS of 124.40 cents.
Jarden forecasts a full year FY28 dividend of 110.00 cents and EPS of 134.70 cents.
Access Extra Coverage Research History >

SHL STOCK CHART

FNArena News on SHL

1
Rudi’s View: August Delivers Soft Guidance, Higher Dividends

Aug 26 2026 - Rudi's View
2
Australian Broker Call *Extra* Edition – Aug 24, 2026

Aug 24 2026 - Daily Market Reports
3
Weekly Ratings, Targets, Forecast Changes – 21-08-26

Aug 24 2026 - Weekly Reports
4
FNArena Corporate Results Monitor – 21-08-2026

Aug 21 2026 - Australia
5
In Brief: Vista, Amcor & Charter Hall Social Infra

Aug 07 2026 - Weekly Reports

Latest Healthcare services News

1
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest
2
Major UK Win Highlights Alcidion’s Potential

May 27 2026 - Small Caps
3
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
4
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
5
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
6
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
7
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
8
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
9
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
10
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps